| Progress toward oligonucleotide therapeutics: pharmacodynamic properties. | |
| | |
MedLine Citation:
|
PMID: 7682523 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Although many issues remain to be resolved, recent progress suggests that oligonucleotides may have therapeutic potential. The first therapeutic oligonucleotide, ISIS 2105, an oligonucleotide designed to treat genital warts, has completed Phase I clinical trials and is undergoing Phase II testing. Conceptually, oligonucleotides may interact with nucleic acid or nonnucleic acid receptors; however, rational design of oligonucleotide drugs to interact with nucleic acid receptors is significantly simpler because the factors that determine affinity and selectivity are better understood. Recent progress demonstrates that this information can be coupled to rapid advances in the medicinal chemistry of oligonucleotides to create new generations of oligonucleotide drugs with dramatically improved properties. The purposes of this review are to place oligonucleotide therapeutics in the context of modern molecular drug discovery and to summarize progress in understanding the pharmacodynamic properties of oligonucleotides designed to bind to nucleic acid receptors. The pharmacokinetic and toxicologic properties of oligonucleotides have been reviewed recently (1-4). The activities of oligonucleotides that bind to nonnucleic acid receptors will be considered in future reviews. |
| | |
Authors:
|
S T Crooke |
Related Documents
:
|
22436143 - Using small molecule reagents to selectively modify epitopes based on their conformation. 20680573 - Improved protocol for high-quality co-extraction of dna and rna from rumen digesta. 3953793 - Absorption of pantothenic acid in rat and chick intestine. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: FASEB journal : official publication of the Federation of American Societies for Experimental Biology Volume: 7 ISSN: 0892-6638 ISO Abbreviation: FASEB J. Publication Date: 1993 Apr |
Date Detail:
|
Created Date: 1993-05-18 Completed Date: 1993-05-18 Revised Date: 2012-02-15 |
Medline Journal Info:
|
Nlm Unique ID: 8804484 Medline TA: FASEB J Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 533-9 Citation Subset: IM |
Affiliation:
|
Isis Pharmaceuticals, Carlsbad, California 92008. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Humans Oligonucleotides / metabolism, pharmacology, therapeutic use* RNA / metabolism |
| Chemical | |
Reg. No./Substance:
|
0/Oligonucleotides; 63231-63-0/RNA |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Retinoid-dependent transcriptional suppression of cytokeratin gene expression in human epidermal squ...
Next Document: Identification of increased nitric oxide biosynthesis during pregnancy in rats.